Table 2.

Systematic reviews of randomized controlled trials involving platelet-rich plasma for hip osteoarthritis. ^*Not a comprehensive list. N refers to the total number of hips that underwent treatment with PRP or HA in each study. Age and follow-up are reported as mean, with the “Total” row reported as weighted mean. HA, hyaluronic acid; HHS, Harris Hip Score, LOE, level of evidence; PRP, platelet-rich plasma; VAS, visual analog scale; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index

Study	LOE	N (PRP, HA)	Patient Age (PRP, HA), years	Follow-Up (PRP, HA), months	Outcomes Reported	Outcomes
Belk et al., 2022 [7]	II	211, 197	60.0, 62.3	12.2, 11.9	WOMAC, VAS, HHS, hip survivorship	No significant difference between groups at final follow-up
Sambe et al., 2023 [12]	II	246, 232	61.0, 63.2	12.2, 11.9	WOMAC, VAS, HHS	No significant difference between groups at final follow-up
Total	-	457, 429	60.5, 62.8	12.2, 11.9	-	-